Phase II study on gemtuzumab ozogamicin in combination with all-trans-retinoic acid [tretinoin], high-dose cytarabine and mitoxantrone in patients with primary refractory acute myeloid leukaemia.

Trial Profile

Phase II study on gemtuzumab ozogamicin in combination with all-trans-retinoic acid [tretinoin], high-dose cytarabine and mitoxantrone in patients with primary refractory acute myeloid leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2010

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Mitoxantrone; Tretinoin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms GO-A-HAM
  • Most Recent Events

    • 11 Aug 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 11 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top